Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Crispr Therapeutics Ag (CRSP)

Crispr Therapeutics Ag (CRSP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,036,220
  • Shares Outstanding, K 55,204
  • Annual Sales, $ 3,120 K
  • Annual Income, $ -164,980 K
  • 60-Month Beta 3.15
  • Price/Sales 946.81
  • Price/Cash Flow N/A
  • Price/Book 4.57

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 0.04
  • Number of Estimates 3
  • High Estimate 0.07
  • Low Estimate 0.01
  • Prior Year -0.92
  • Growth Rate Est. (year over year) +104.35%

Price Performance

See More
Period Period Low Period High Performance
1-Month
36.65 +49.60%
on 10/15/19
56.16 -2.37%
on 11/12/19
+18.15 (+49.48%)
since 10/14/19
3-Month
35.46 +54.62%
on 10/10/19
56.16 -2.37%
on 11/12/19
+8.56 (+18.50%)
since 08/14/19
52-Week
22.22 +146.75%
on 12/21/18
56.16 -2.37%
on 11/12/19
+20.07 (+57.73%)
since 11/14/18

Most Recent Stories

More News
Editas (EDIT) Beats on Q3 Earnings, Amends Celgene Deal

Editas' (EDIT) portfolio currently lacks an approved product. The focus of third-quarter earnings call was on its pipeline development.

AGN : 182.47 (+0.48%)
CELG : 110.02 (-0.35%)
EDIT : 22.66 (-1.44%)
CRSP : 55.06 (+0.11%)
Vertex (VRTX) Q3 Earnings Beat, Revenues Lag Estimates

Vertex (VRTX) encourages investors with better-than-expected earnings in Q3. However, the top line misses the mark.

ACOR : 1.83 (-5.18%)
ANIK : 59.77 (-1.26%)
VRTX : 205.00 (-1.01%)
CRSP : 55.06 (+0.11%)
Vertex (VRTX) Q3 Earnings Beat, Revenues Lag Estimates

Vertex (VRTX) encourages investors with better-than-expected earnings in Q3. However, the top line misses the mark.

ACOR : 1.83 (-5.18%)
ANIK : 59.77 (-1.26%)
VRTX : 205.00 (-1.01%)
CRSP : 55.06 (+0.11%)
Investors Can Find Strong Stocks with our First Profit Screen

Investors Can Find Strong Stocks with our First Profit Screen

KOS : 7.08 (-3.15%)
FB : 193.15 (-0.02%)
CRSP : 55.06 (+0.11%)
CPRX : 4.70 (+3.52%)
CHRS : 18.98 (-1.15%)
BRFS : 7.81 (-0.26%)
AAPL : 262.64 (-0.69%)
CRISPR Therapeutics AG (CRSP) Q3 Earnings and Revenues Surpass Estimates

CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of 352.63% and 3252.23%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the...

CRSP : 55.06 (+0.11%)
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2019 Financial Results

-Provides update from ongoing Phase 1/2 clinical trials of CTX001(R) for patients with severe hemoglobinopathies-

CRSP : 55.06 (+0.11%)
Can CF Drugs Drive Growth for Vertex (VRTX) in Q3 Earnings?

During Vertex's (VRTX) third-quarter earnings call, investor focus will be on the uptake of its newest CF drug Symdeko and the update on the recent approval of Trikafta triple combination regimen.

AMGN : 218.50 (-0.53%)
VRTX : 205.00 (-1.01%)
INCY : 85.79 (-1.88%)
CRSP : 55.06 (+0.11%)
Navigating The Healthcare Industry: Science Fiction Turns to Reality

Kevin Cook joins us to help walk us through the maze that is the healthcare industry. We touch on everything from the hottest trends all the way down to how to pick a winning stock!

IBB : 109.85 (-0.66%)
XBI : 83.67 (-0.68%)
SBIO : 35.65 (-0.42%)
EW : 240.56 (-0.75%)
GWPH : 106.01 (-4.52%)
FOMX : 3.44 (-3.10%)
CRSP : 55.06 (+0.11%)
ARKG : 31.10 (-0.89%)
CRISPR Therapeutics and Bayer Announce an Update on Casebia Therapeutics

CRISPR Therapeutics and Bayer today announced proposed plans whereby Casebia Therapeutics, a joint venture between CRISPR Therapeutics and Bayer, would operate under the direct management of CRISPR Therapeutics....

CRSP : 55.06 (+0.11%)
Earnings Season Makes Good First Impression

Earnings Season Makes Good First Impression

VNE : 16.10 (+0.12%)
EXTR : 6.58 (-1.20%)
NMRK : 12.20 (-0.89%)
ALNY : 90.46 (-0.13%)
CRSP : 55.06 (+0.11%)
QCOM : 90.48 (+0.01%)
GO : 31.84 (+0.82%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade CRSP with:

Business Summary

CRISPR Therapeutics AG is a gene-editing company. It focused on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.

See More

Key Turning Points

2nd Resistance Point 57.96
1st Resistance Point 56.48
Last Price 55.06
1st Support Level 53.04
2nd Support Level 51.08

See More

52-Week High 56.16
Last Price 55.06
Fibonacci 61.8% 43.19
Fibonacci 50% 39.19
Fibonacci 38.2% 35.19
52-Week Low 22.22

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar